Atea Pharmaceuticals, INC DEF 14A proxy statements

Atea Pharmaceuticals announces its 2026 Annual Meeting of Stockholders, focusing on director elections, executive compensation, and clinical pipeline progress.

Atea Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on June 20, 2025, featuring proposals for director elections, auditor ratification, and executive compensation approval.

Atea Pharmaceuticals responds to shareholder nominations for board positions, emphasizing its commitment to its Phase 3 HCV program and ongoing dialogue with investors.

Driver Opportunity Partners III withdraws its nomination for J. Abbott R. Cooper to Atea Pharmaceuticals' Board of Directors at the upcoming 2025 Annual Meeting of Stockholders.

Atea Pharmaceuticals is undertaking a strategic review, cost-cutting measures, and board enhancements to improve shareholder value.

Atea Pharmaceuticals acknowledges receipt of director nominations from shareholders Bradley L. Radoff and Driver Opportunity Partners III LP for the upcoming 2025 Annual Meeting.

Atea Pharmaceuticals clarifies the benefits of director Franklin Berger's multiple board memberships ahead of the vote for his re-election at the annual meeting.

Atea Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on June 21, 2024, outlining key voting items including the election of directors and ratification of the company's independent auditor.

Atea Pharmaceuticals will hold its annual stockholders meeting virtually on June 21, 2024, to vote on director elections, auditor ratification, and executive compensation.